- Home
- THFF vs APMD Comparison
THFF vs APMD Comparison
Compare THFF & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THFF | APMD |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 881.8M | 895.5M |
| IPO Year | 1995 | 2026 |
Fundamental Metrics
Financial Performance| Metric | THFF | APMD |
|---|---|---|
| Price | $76.07 | $15.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $85.33 | $50.33 |
| AVG Volume (30 Days) | 132.0K | ★ 385.9K |
| Earning Date | 10-27-2026 | 11-17-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 67.00 | N/A |
| EPS | ★ 5.89 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.67 | $136.18 |
| Revenue Next Year | $16.17 | N/A |
| P/E Ratio | $13.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.76 | $14.65 |
| 52 Week High | $84.17 | $35.29 |
Technical Indicators
Market Signals| Indicator | THFF | APMD |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 35.25 |
| Support Level | $74.32 | N/A |
| Resistance Level | $78.70 | $19.83 |
| Average True Range (ATR) | 1.96 | 1.54 |
| MACD | 0.18 | -0.13 |
| Stochastic Oscillator | 33.52 | 20.17 |
Price Performance
Historical ComparisonAbout THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities. Company's loan portfolio was diversified in Commercial, Residential and consumer domains.
About APMD Apnimed Inc. Common Stock
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).